Form 4: Roivant CFO Sells Shares for Tax Obligations

Roivant Sciences Ltd. CFO Richard Pulik disposed of 1,546 common shares to cover tax withholding obligations related to RSU vesting.

Summary

• Richard Pulik, the Chief Financial Officer of Roivant Sciences Ltd., reported a transaction involving the company's common shares.
• On March 20, 2026, Mr. Pulik disposed of 1,546 common shares.
• The disposition was a 'net settlement' by the Issuer of previously granted Restricted Stock Units (RSUs) to satisfy applicable tax withholding obligations.
• The shares were disposed of at a price of $27.7 per share.
• Following this transaction, Mr. Pulik beneficially owns 236,867 common shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. It is a standard, non-discretionary transaction related to executive compensation and tax obligations, with no direct implications for the company's operational performance or strategic direction.

Positives

• The transaction represents a routine event related to the vesting of equity compensation (RSUs), indicating the executive's continued alignment with shareholder interests through equity ownership.
• The disposition was for tax withholding purposes, not a discretionary sale, which is a standard practice for executives receiving equity awards.

Negatives

• The number of directly beneficially owned common shares by the CFO decreased by 1,546 shares as a result of the tax settlement.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

StockSavvy.ai notes that transactions involving the 'net settlement' of RSUs to cover tax obligations are a common and routine occurrence for executives in publicly traded companies across all industries. This mechanism allows executives to receive the net benefit of their equity awards while fulfilling their tax liabilities without needing to use personal funds.

Comparison to Industry Standards

• The practice of net settlement for RSU tax withholding is a widely accepted and standard procedure in corporate compensation, aligning with practices observed in major pharmaceutical and biotechnology companies globally.
• Comparable companies like Pfizer, Merck, and Johnson & Johnson frequently report similar Form 4 transactions for their executives, indicating this is a standard operational aspect of equity compensation plans.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine tax-related transaction and not a discretionary sale indicating a change in management's confidence.
• Employees: No direct impact on the broader employee base.

Key Dates

Keywords

Roivant Sciences, ROIV, Form 4, Insider Transaction, CFO, Richard Pulik, Restricted Stock Units, RSU, Tax Withholding, Equity Compensation, Share Disposition